Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$80.36 USD

80.36
1,940,935

-0.80 (-0.99%)

Updated Sep 11, 2024 01:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (30 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge

Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.

Bayer & JNJ Settle Numerous Xarelto Lawsuits for $775 Million

Bayer (BAYRY) and partner Johnson & Johnson settle about 25,000 claims over blood thinner, Xarelto for $775 million.

AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes

AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.

Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market

Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.

The Zacks Analyst Blog Highlights: Las Vegas Sands, Phillips 66, AstraZeneca, Hilton and AutoZone

The Zacks Analyst Blog Highlights: Las Vegas Sands, Phillips 66, AstraZeneca, Hilton and AutoZone

Mark Vickery headshot

Top Stock Reports for Las Vegas Sands, Phillips 66 & AstraZeneca

Today's Research Daily features new research reports on 16 major stocks, including Las Vegas Sands (LVS), Phillips 66 (PSX) and AstraZeneca (AZN).

The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores

The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores

PhaseBio Stock Up on Positive Data From PB2452 Phase I Study

PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.

Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer

Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

Kinjel Shah headshot

Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?

Pipeline success, cost-cutting measures, share buybacks, product launches, ramped up M&A and collaboration activities should keep the sector afloat, going forward.

Novartis' (NVS) Alcon Acquired PowerVision for $285 Million

Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.

Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.

AstraZeneca Up This Year on New Drugs & Pipeline Progress

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

Mark Vickery headshot

Top Research Reports for Merck, Adobe & Broadcom

Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Adobe (ADBE) and Broadcom (AVGO).

AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag

AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in Q4. However, revenues fall shy of estimates.

Merck's Keytruda Gets EU Approval for Difficult Lung Cancer

Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.

Here's Why Momentum Investors Will Love Astrazeneca (AZN)

Does Astrazeneca (AZN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Swarup Gupta headshot

Is Britain Headed for a Soft Brexit? 5 Picks

Following May's fresh legislative defeat, Britain could exit the EU while retaining access to its common market.

Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down

Inovio Pharmaceuticals (INO) reports results for fourth quarter of 2018 wherein loss and revenues both miss estimates.

Bayer Submits Application in EU for Prostate Cancer Drug

Bayer (BAYRY) submits an MAA for darolutamide in EU for the treatment of patients with non-metastatic castration-resistant prostate cancer.

Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps

Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.

The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's

The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's

Should Value Investors Pick AstraZeneca PLC (AZN) Stock?

Is AstraZeneca PLC (AZN) a great pick from the value investor's perspective right now? Read on to know more.

Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs

J&J's (JNJ) Spravato (esketamine) gets approval for treatment-resistant depression. CHMP recommends approval of several drugs.

J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression

J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression